Alanna Gerhardt
Gerontology · East Stroudsburg, PANPI 1992236012
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.1% of the total across 152 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 21.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $1,563 and has fallen 70.7% since, to $458 in 2025. Among gerontology clinicians in PA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 152 payments — averaging $18.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$584
- Novo Nordisk$367
- Xeris Pharmaceuticals, Inc.$253
- Lilly USA, LLC$246
- Dexcom, Inc.$178
- Abbott$167
- plus $972 from 16 others
What the payments were for
- Food & beverage$2,74299%
- Education$251%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 33 | $584 |
| Novo Nordisk | 22 | $367 |
| Xeris Pharmaceuticals, Inc. | 13 | $253 |
| Lilly USA, LLC | 20 | $246 |
| Dexcom, Inc. | 11 | $178 |
| Abbott | 8 | $167 |
| Boehringer Ingelheim | 7 | $164 |
| Sanofi-aventis U.S. LLC | 8 | $151 |
| Bayer | 5 | $118 |
| Sequel Med Tech, LLC | 1 | $93 |
| Amgen(2 entities) | 6 | $87 |
| Mannkind Corporation | 4 | $74 |
| AstraZeneca | 3 | $54 |
| BD | 2 | $45 |
| Embecta Corp. | 1 | $34 |
| Radius Health, Inc. | 2 | $32 |
| Antares Pharma, Inc. | 1 | $24 |
| Halozyme Inc | 1 | $24 |
| Ascendis Pharma Endocrinology Inc | 1 | $22 |
| Tandem Diabetes Care, Inc. | 1 | $19 |
| Insulet Corporation | 1 | $18 |
| IBSA Pharma Inc. | 1 | $16 |
How this compares
$2,767 in reported general payments places this provider in the 90th percentile of 383 gerontology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 212 | $343,595 |
| TrulicityDulaglutide | 239 | $341,564 |
| JardianceEmpagliflozin | 241 | $308,021 |
| JanuviaSitagliptin Phosphate | 125 | $156,805 |
| MounjaroTirzepatide | 80 | $107,532 |
| RybelsusSemaglutide | 41 | $84,303 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 37 | $63,989 |
| Tresiba Flextouch U-200Insulin Degludec | 50 | $60,888 |
| FarxigaDapagliflozin Propanediol | 52 | $56,687 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 35 | $47,842 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 63 | $39,368 |
| Tresiba Flextouch U-100Insulin Degludec | 56 | $38,901 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 69 | $33,061 |
| TradjentaLinagliptin | 30 | $31,473 |
| Novolog FlexpenInsulin Aspart | 132 | $28,815 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Fiasp, Novolog | $367 | $469,530323 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $246 | $456,702348 claims |
| Boehringer IngelheimJardiance, Tradjenta, Synjardy | $164 | $355,267282 claims |
| AstraZenecaFarxiga | $54 | $56,68752 claims |
| Sanofi-aventis U.S. LLCLantus | $151 | $5,83038 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 383 gerontology providers in Pennsylvania.
Other gerontology in East Stroudsburg
- Susan ScanlandScranton$517K
- Michelle BalbiAllentown$257K
- Melissa CallahanEphrata$76K
- Maria BonanniPhiladelphia$36K
- Lisa DevaneyWest Chester$27K
- Lora DillingerWyomissing$21K
- Laken KuntzMonroeville$14K
- Kelly ShearerPittsburgh$12K
- Alanna MillerPhiladelphia$9K
- Mary KelleyPhiladelphia$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.